This column highlights some of the more notable recent online notices, newsletters, and blogs dealing with IP prosecution issues.
IPWatchdog – a patents and patent law blog – IPwatchdog.com
- On February 22, 2019, IPWatchdog remarked that bipartisan meetings in Congress are searching for legislative solutions to the Section 101 patent eligibility problems involving biotechnology, medical diagnostics, and software-related inventions. (details here).
- On February 5, 2019, Hans Sauer discussed the recent Helsinn v. Teva (PDF here), Supreme Court opinion regarding secret sales as public use bars. This article maintains that the scope of prior art is now uncertain instead of what was thought to confirm longstanding law. (details here).
Patent Docs – A patent blog – patentdocs.typepad.com/patent_docs
- In the February 6, 2019 post, Donald Zuhn mentioned that the USPTO issued its Fiscal Year 2018 “Performance and Accountability Report” (PDF here) providing statistics and describes agency goals.. (details here).
- Donald Zuhn’s February 17, 2019 post noted that the USPTO extended the Cancer Immunotherapy Pilot Program to June 30, 2020, but the Extended Missing Parts Pilot Program ended on January 2, 2019. (details here).
AIPLA – the profession’s national organization – see AIPLA.org
- AIPLA will hold its 2019 Annual Meeting October 24-26, 2019 in Washington, D.C. More information on this meeting and other events is available here.
- The Chisum Patent Academy holds upcoming patent law seminars in Seattle, Washington on August 8-9, 2019. Complete syllabi for all Chisum seminars are available here. There are a possible 18 CLE credits for these seminars. Each seminar is limited to ten attendees. More info here.
For more information about any of the patent topics mentioned consult Patent Application Practice. Trademark topics are discussed in Trademark Registration Practice. Both are published by West and updated twice a year. For patent prosecution or litigation questions, contact Fred Douglas at 949-293-0442 or by email at email@example.com.